25 October 2016AmericasMarcelo Oliveira de Souza and Antonio Alexandre Moura dos Santos
Doubling up: biotech patent examination in Brazil
The merging of intellectual property law and biotechnology represents the joining of old law with new technology. In theory, statutes designed to facilitate creation of unforeseen technologies and reward inventors for their creativity should blend easily with the inventions of biotechnology. Although IP laws have fostered research and development in biotechnology, new legal and social questions have also arisen.
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
26 February 2026 As the US Supreme Court prepares to hear arguments in the Hikma and Amarin dispute, the case has drawn a broad coalition of industry support—including the US government and a co-author of the Hatch-Waxman Act itself.
26 February 2026 In a decision with implications for biotechnology licensing and pharmaceutical manufacturing, the Ninth Circuit has rejected a ‘sweeping’ royalty trigger from a lower court.
25 February 2026 The Danish company is contending with fierce competition, a clinical trial setback and a UK boost to its main rival, while making new moves to enforce its weight-loss-drug IP.